Mp69-16 Assessing the Risk of Urinary Tract Infections Associated With Sglt2 Inhibitors in Men: A Vigibase Analysis

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Kidney EBE, 6.99) as well as in those 65 years and older (ROR, 5.11; EBE, 5.44). CONCLUSIONS: In this pharmacovigilance study utilizing VigiBase, we examined the potential association between UTI risk and SGLT2 inhibitors. Our findings suggest a possible elevated UTI risk with these medications. Interestingly, being over the age of 65, often used as a surrogate for BPH, did not seem to further increase this risk. While SGLT2 inhibitors continue to gain traction as a preferred antidiabetic treatment, it would be prudent for providers to be aware of the potential UTI risk, especially in populations more susceptible to UTIs. Further studies are needed to corroborate these findings. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1125 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Zhiyu Qian More articles by this author Jonathan Song More articles by this author Brian Tao More articles by this author Boyuan Xiao More articles by this author Dejan K. Filipas More articles by this author Edoardo Beatrici More articles by this author Daniel R. Stelzl More articles by this author Muhieddine Labban More articles by this author Benjamin J. Stone More articles by this author Hari S. Iyer More articles by this author Stuart R. Lipsitz More articles by this author Alexander P. Cole More articles by this author Quoc-Dien Trinh More articles by this author Expand All Advertisement PDF downloadLoading ...